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ABSTRACT  
Oxysterols are oxygenated derivatives of cholesterol characterized by a very short half-
life and their ability to pass lipophilic membranes easily, and they are considered as 
important intermediates in the excretion pathways of cholesterol and its conversion to 
bile acids. Evidence has been presented that the production and flux of oxysterols in the 
brain may also be of some importance for cognitive functions. The two major 
oxysterols in the circulation of human and mouse are 24S-hydroxycholesterol (24S-
OH) and 27-hydroxycholesterol (27-OH), which are formed by the cytochrome P450 
enzymes cholesterol 24-hydroxylase (CYP46A1) and sterol 27-hydroxylase 
(CYP27A1), respectively. The two oxysterols 27-OH and 24S-OH are both strong 
inhibitors of cholesterol synthesis and activators of LXR in vitro. However, their role as 
physiological regulators under in vivo conditions is controversial. 
 
The overall aim of this thesis was to investigate the regulatory role of side-chain 
oxidized oxysterols as metabolic regulators in vivo. In particular, we have studied the 
role of 24S-OH and 27-OH as regulators of cholesterol synthesis and activators of 
LXR. We used mouse models with increased levels of 27-OH like human CYP27A1 
overexpressor mice (CYP27A1tg) and Cyp7b1 knockout mice (Cyp7b1-/-), as well as a 
mouse model with no detectable levels of 27-OH in the circulation, Cyp27a1 knockout 
mice (Cyp 27a1-/-). The latter mice were treated with cholic acid to compensate for the 
reduced formation of bile acids. Using Cyp27a1-/- mice, we have also studied the 
possibility that 27-OH mediates the negative effects of dietary cholesterol on memory 
function in mice. 
 
In Paper I, we studied a possible regulatory role of 27-OH and 24S-OH in the brain, 
using CYP27A1tg mice and Cyp27a1-/- mice. The levels of 27-OH were increased by 
approximately 12-fold in the brain of CYP27A1tg mice while levels of 24S-OH were 
decreased by about 25%, most probably due to increased metabolism by the CYP27A1 
enzyme. Evidence was presented that cholesterol synthesis was increased in the brain 
of the two mouse models. There was no upregulation of the LXR-target genes in the 
brain of either of the two models. The increased synthesis in the brain of the Cyp27a1-/- 
mice is probably the consequence of the absence of an inhibitory effect of the flux of 
27-OH into the brain. The increased cholesterol synthesis in the brain of the 
CYP27A1tg mice is probably due to the reduced levels of 24S-OH, leading to reduced 
inhibition of its synthesis. The results of this study are consistent with the possibility 
that both 24S-OH and 27-OH have a suppressive effect on cholesterol synthesis in the 
brain. We also conclude that 27-OH is not a general activator of LXR in this tissue. 
 
In Paper II, we examined the role of 27-OH in the liver using the three mouse models 
described above. Only very modest effects on cholesterol synthesis and LXR target 
genes were observed in the three mouse models.  The overall results do not support the 
contention either that 27-OH is an important regulator of cholesterol homeostasis, or 
that 27-OH is an activator of LXR-regulated genes under basal conditions in the liver. 
It has been reported that treatment of mice with dietary cholesterol leads to 
upregulation of some LXR target genes in the liver. In a study by Chen et al, such 
upregulation of three different LXR target genes was not seen when treating mice 
  
lacking 24S-OH, 25-OH and 27-OH with dietary cholesterol (Chen et al., 2007). It was 
concluded that a 24-, 25- or 27-hydroxylation step mediated the effect of dietary 
cholesterol. We show here that similar effects were obtained when treating Cyp27a1-/- 
mice with dietary cholesterol, suggesting that the effects are mediated by 27-OH. Most 
of these effects could however not be observed at either the protein level, or at the level 
of enzyme activity.   
The results suggest that 27-OH is a mediator of the cholesterol-induced effects on some 
LXR target genes when the mice are challenged with a high load of dietary cholesterol. 
The physiological importance of this effect is difficult to evaluate. 
 
In Paper III we compared the two mouse models CYP27A1tg and Cyp7b1-/- mice, both 
of which have high levels of 27-OH in the circulation and the brain. In contrast to 
CYP27A1tg mice, the levels of 24S-OH in the brain were not decreased in the latter 
model, and cholesterol synthesis was not affected. This supports the proposal that 24S-
OH is of regulatory importance for cholesterol synthesis in the brain. It has been 
reported that cholesterol synthesis is reduced in the kidney of Cyp7b1-/- mice. 
Cholesterol synthesis in the kidney of CYP27A1tg mice was not affected, however. We 
conclude that factors other than high levels of 27-OH are of importance for the reduced 
cholesterol synthesis in the kidney of the Cyp7b1-/- mice. 
 
In Paper IV we tested the possibility that the negative effect of dietary cholesterol on 
cognition in mice is mediated by 27-OH. The negative effect of dietary cholesterol on 
spatial memory observed in wild-type mice was not observed in Cyp27a1-/- mice. The 
latter mice were also treated with cholic acid to compensate for the reduced synthesis of 
bile acids. Treatment with dietary cholesterol was shown to lead to reduced levels of 
the “memory protein” Arc (Activity-Regulated Cytoskeleton-associated protein) in the 
hippocampus of the wildtype mice. This effect was not seen in the hippocampus of 
Cyp27a1-/- mice. The results are consistent with the possibility that 27-OH is a mediator 
of the negative effects of dietary cholesterol on cognition.   
 
In conclusion, our results suggest that both 24S-OH and 27-OH may be of some 
regulatory importance for cholesterol synthesis in the brain but not in the liver. Under 
normal basal conditions 27-OH does not seem to be a general activator of LXR, either 
in the brain or in the liver. We discuss the possibility that the different effects on 
cholesterol synthesis in the two organs may be related to the fact that almost all 
oxysterols in the brain are in the free form, whereas in the liver, most of them are 
esterified. In addition, we demonstrate that the negative effects of dietary cholesterol on 
cognition is mediated by 27-hydroxylation. 
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1 BACKGROUND 
1.1 CHOLESTEROL 
Cholesterol is a hydrophobic molecule with the molecular formula C27H45OH and four 
rings in its structure. It is a vital structural component of all mammalian cell 
membranes, and is necessary for proper membrane permeability and fluidity. In 
addition, cholesterol functions as an important precursor for the biosynthesis of steroid 
hormones and bile acids. 
 
1.1.1 Cholesterol synthesis and its regulatory mechanisms 
Cholesterol is synthesized by almost all types of mammalian cells, in particular in the 
liver and intestine (Dietschy et al., 1993). Cholesterol synthesis occurs in five main 
steps illustrated in figure 1; 1) Condensation of three acetyl-CoA molecules to form 3-
hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) (Bloch, 1987); 2) Conversion of HMG-
CoA to mevalonate. This reaction is catalyzed by the enzyme HMG-CoA reductase 
(HMGCR), which is the rate-limiting step in the cholesterol synthesis pathway 
(Goldstein and Brown, 1990); 3) Formation of the five carbon structure isopentenyl-PP 
from mevalonate. Isopentenyl-PP is the precursor not only for cholesterol but also for 
many non-steroidal isoprenoid molecules that are of importance for prenylation of 
different proteins within the cell; 4) Generation of the 30 carbon atom structure 
squalene from the isopentenyl-PP through multiple steps; 5) conversion of squalene 
into lanosterol, which is then converted to cholesterol through a series of reactions. 
   
                
    
Figure 1. A simplified overview of cholesterol biosynthesis. Cholesterol synthesis also results in 
production of non-steroidal isoprenoid molecules (geranyl geranol-PP). PP; pyrophosphate. The latter 
metabolites may be used for geranylation of a number of proteins. 
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Cholesterol biosynthesis, uptake and turn-over by the cells are among the most tightly-
regulated processes in cells. The rate-limiting enzyme in cholesterol biosynthesis, 
HMGCR, is competitively inhibited by the cholesterol-lowering drug statin (Stancu and 
Sima, 2001). Sterol regulatory element binding proteins (SREBPs) are endoplasmic 
reticulum (ER) membrane-bound transcription factors able to regulate multiple genes 
involved in cholesterol and fatty acids biosynthesis and uptake (Brown and Goldstein, 
1999). There are three isoforms of SREBP. SREBP-1a and SREBP-1c are produced by 
the same gene and mainly control genes involved in fatty acid synthesis. SREBP-2 is 
encoded by a separate gene and controls the transcription of genes involved in 
cholesterol synthesis (e.g. HMGCR) and uptake (low-density lipoprotein-receptor 
(LDL-R) ) (Brown and Goldstein, 1997). In the ER membrane, SREPB-2 is bound to 
the SREBP-cleavage activating protein (SCAP) which forms a complex with the 
anchor protein insulin-induced gene (INSIG) in the presence of high cholesterol 
concentrations. SCAP serves as a cholesterol level sensor due to the presence of a 
specific intra-membrane sequence called the sterol sensing domain (SSD). When 
cholesterol levels drop in the cell, the SREBP-2/SCAP complex is released from the 
anchor protein INSIG and transported to the Golgi, where it is subjected to enzymatic 
cleavage by two proteases with subsequent release of the active form of SREBP-2. The 
latter protein enters the nucleus and exerts its action by binding to sterol regulatory 
elements (SREs) in target genes (Goldstein et al., 2006). 
 
HMGCR has a sterol sensing domain (SSD) similar to that in SCAP. When the 
concentration of sterols increases in the ER, this will induce binding of the reductase 
enzyme to the ER proteins INSIG-1 and INSIG-2. This leads to recruitment of a 
membrane-associated ubiquitin ligase that initiates ubiquitination and subsequent 
degradation of the HMGCR (Sever et al., 2003). The cholesterol synthesis pathway can 
also be rapidly regulated by phosphorylation and dephosphorylation of the enzyme 
HMGCR. This enzyme is most active in its unmodified form, and phosphorylation by 
adenosine monophosphate protein kinase (AMK) decreases its activity (Corton et al., 
1994; Hardie, 2003). 
 
1.1.2 Cholesterol absorption and transportation 
Cholesterol is a hydrophobic molecule, which must be associated with lipoproteins to 
enable its transport in the blood stream. Dietary cholesterol is absorbed from the 
intestinal lumen and delivered to the liver by chylomicrons. In the liver, cholesterol 
may be stored as cholesteryl esters by the action of the enzyme acyl coenzyme A: 
cholesterol acyltransferase (ACAT), converted to bile acids, secreted directly in the 
bile, or packed in the very low density lipoprotein (VLDL) particles. In the circulation, 
the triglyceride core of VLDL is subjected to lipolysis by the lipoprotein lipase and 
apolipoproteins A and C are transferred to high-density lipoprotein (HDL). Eventually, 
hydrolysis of VLDL remnants by hepatic lipase will lead to formation of low-density 
lipoprotein (LDL), which contains a relatively high cholesterol content. LDL delivers 
cholesterol to target tissues through interaction with the LDL-R. 
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1.1.3 Cholesterol elimination 
Cholesterol is essential for the cells, but at the same time excess free cholesterol is 
toxic. Thus it is important to keep cholesterol levels under control by different 
mechanisms. Cholesterol is converted to cholesterol esters by the action of the enzymes 
ACAT and lecithin: cholesterol acyltransferase (LCAT) in cells and in the circulation, 
respectively. The unesterified cholesterol is transported to the liver in HDL particles. 
Lipidation of HDL is facilitated by the transmembrane ATP-binding cassette 
transporter A1 (ABCA1). HDL is then taken up by the liver, where the cholesterol is 
metabolized. The flux of excess cholesterol from the peripheral tissues to the liver by 
HDL is called reverse cholesterol transportation (RCT). 
 
Another major route for elimination of excess cholesterol from the body is by secretion 
into the bile (via ABCG5/ABCG8) as free cholesterol for subsequent elimination in the 
faeces (Graf et al., 2003). Extrahepatic tissues can also convert cholesterol into a 
hydroxycholesterol by the action of the cytochrome P-450 enzyme CYP27A1 (see 
below). This 27-hydroxylation of cholesterol allows rapid passage through the cell 
membrane followed by transportation in the lipoproteins back to the liver. 
 
 
1.2 BILE ACIDS 
Bile acids are necessary for emulsification and absorption of dietary lipids, cholesterol 
and lipid-soluble vitamins in the intestine. The synthesis of bile acids takes place in the 
liver, where approximately 500 mg of cholesterol is converted into bile acids daily. 
After secretion of the bile into the intestine about 95% of the bile acids are reabsorbed 
and returned to the liver in what is called enterohepatic circulation. About 300-500 mg 
of bile acids avoids this cycle and are excreted in the faeces daily. The liver 
compensates for this loss by replacing it with newly synthesized bile acids 
(~500mg/day), and this is one of the two major mechanisms by which excess 
cholesterol is eliminated from the body. 
 
The enzymatic conversion of cholesterol into its oxygenated derivatives and eventually 
to bile acid is mainly catalysed by a group of microsomal and mitochondrial enzymes 
named the cytochrome P450s (Norlin and Wikvall, 2007). These enzymes are 
monooxygenases, possess a heme molecule as a cofactor, and use NADPH as an 
electron source (Danielson, 2002). 
 
The process of bile acid synthesis involves multiple enzymes and takes two major 
pathways, the classical (neutral) and the alternative (acidic) (Russell, 2003). The first 
step in the classical pathway is catalyzed by the rate limiting enzyme cholesterol 7α-
hydroxylase (CYP7A1) resulting in the production of cholic acid (CA) and 
chenodexoycholic acid (CDCA) with CA as the major product. In the alternative 
pathway CDCA is formed predominantly. The alternative pathway is initiated by the 
sterol 27-hydroxylase (CYP27A1) and is believed to contribute to about 25% of the 
formation of bile acids in rodents. Knockout of the gene Cyp27a1 in mice results in a 
severe reduction in bile acid synthesis (by about 70%). As a consequence of decreased 
levels of bile acids, these mice also show decreased intestinal cholesterol absorption 
and increased cholesterol synthesis. As a compensatory mechanism, Cyp7a1 is 
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upregulated in mutant mice (Rosen et al., 1998; Repa et al., 2000b). Feeding with 
cholic acid normalizes the metabolic disturbance in these mice. Unlike mice, a mutation 
in the human gene CYP27A1 results in accumulation of xanthomas in the brain and 
tendons. This rare disease is called cerebrotendinous xanthomatosis (CTX), and is 
characterized by dementia, ataxia and cataracts (Bjorkhem and Leitersdorf, 2000). 
 
The bile acid pool is auto-regulated by the binding of bile acids to the nuclear receptor 
farnesoid X receptor (FXR) in the liver (Makishima et al., 1999; Chiang, 2004). FXR 
inhibits CYP7A1 transcription by a mechanism involving activation of small 
heterodimer (SHP) and liver receptor homologue 1 (LRH1). Bile acids fluxing into the 
intestine regulate the plasma levels of intestinal fibroblast growth factor (FGF) 19 (in 
mice, FGF15)  that in turn regulates the activity of the enzyme CYP7A1 (Inagaki et al., 
2005; Lundasen et al., 2006). 
 
 
1.3 CHOLESTEROL METABOLISM IN THE BRAIN 
The brain is very rich in cholesterol and its total cholesterol content is estimated to be 
about 25% of the total cholesterol in the body. Almost all of it exists as unesterified 
cholesterol. Most of the brain cholesterol (about 70%) is localized to myelin. The 
myelin sheath is essential for the proper functioning of the brain. Unlike other tissues in 
the body, the brain cholesterol pool is totally isolated from other pools in the body due 
to the blood-brain barrier (BBB), which is impermeable to lipoprotein-bound 
cholesterol in the circulation. All cholesterol found in the brain is thus synthesized in 
situ. Oligodendrocytes, the cells responsible for myelination, and astrocytes are the 
major cells responsible for cholesterol synthesis in the brain (Bjorkhem and Meaney, 
2004). 
 
Cholesterol synthesis in the brain is relatively high during the developmental period but 
reaches a very low level in the adult state. As a consequence, the cholesterol in the 
adult human brain has a long half-life that estimated to be about five years (Bjorkhem 
et al., 1998; Dietschy and Turley, 2004). In spite of this long half-life, the brain still 
needs to eliminate some of its cholesterol to maintain constant levels. About 1-2 
mg/day of cholesterol bound to apolipoprotein E (APOE) is excreted from the brain 
into the cerebrospinal fluid (CSF). However, the conversion of cholesterol into 24S-
hydroxycholesterol (24S-OH) is considered to be the major mechanism for elimination 
of excess cholesterol from the brain (see below). The amount of cholesterol eliminated 
from the human brain through this pathway is estimated to be about 6-7mg/day 
(Bjorkhem et al., 1998). 
 
Neuronal cells are able to synthesize cholesterol but this synthesis is reduced during 
maturation. Therefore neurons are dependent on cholesterol provided by astrocytes 
(Pfrieger, 2003). Astrocytes are also considered to be the main producer of APOE in 
the brain, which is the main transporter protein for cholesterol in the central nervous 
system. APOE-bound cholesterol is taken up by neurons and other cells via LDL-R and 
the LDL receptor-related protein (LRP). Astrocytes also express the membrane 
transporter ABCA1, which is also important for cholesterol flux in the brain (Bjorkhem 
and Meaney, 2004). There are several studies in the literature linking abnormal 
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cholesterol metabolism in the central nervous system (CNS) to the development of  
neurodegenerative diseases such as Niemann-Pick C disease, Huntington’s disease, 
Alzheimer’s disease (AD) and Parkinson’s disease (Block et al., 2010; Madra and 
Sturley, 2010; Wang et al., 2011), indicating the importance of normal and well-
controlled cholesterol homeostasis in the CNS. 
 
 
1.4 SIDE-CHAIN OXIDIZED OXYSTEROLS 
Oxysterols were first identified by Lifschütz (Gill et al., 2008) about one century after 
the characterization of cholesterol. They are oxygenated derivatives of cholesterol and 
can be formed enzymatically and non-enzymatically. They possess a very short half-life 
and the ability to pass lipophilic membranes more easily than cholesterol, making them 
easily redistributed in the body (Lange et al., 1995; Meaney et al., 2002). Oxysterols 
are important intermediates in cholesterol excretion pathways and conversion into bile 
acids. In plasma, they are associated with albumin or plasma lipoproteins. Similar to 
cholesterol, oxysterols are known substrates for ACAT and LCAT in cells and plasma 
respectively (Brown and Jessup, 2009). Oxysterols are predominantly found in the 
esterified form in the circulation and most organs, except for the brain, in which they 
are predominantly in the free form. Sulfation of oxysterols by the enzyme cholesterol 
sulfotransferase (SULT2B1b) is another important route for in-activation and 
elimination of free oxysterols (Chen et al., 2007).  
 
In addition to their important role in cholesterol transportation and elimination, 
oxysterols are involved in different pathological processes, such as atherosclerosis, 
neurodegeneration, inflammation and immunity, osteoporosis, and cancer. In this 
thesis, we are focusing on enzymatically-formed oxysterols, named “side-chain 
oxidized oxysterols”, such as 24S-, 25-, and 27-OH, which are hydroxylated on their 
side chain. The two major oxysterols in the circulation of man and rodents are 24S-OH 
and 27-OH (Bjorkhem, 2009).  
 
 
 
 
Figure 2. Structure and generation of the major side-chain oxidized oxysterols from cholesterol. 
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1.4.1 24S-hydroxycholesterol 
Conversion of brain cholesterol to 24S-OH by the microsomal enzyme cholesterol 24-
hydroxylase (CYP46A1) is considered to be the main mechanism for the elimination of 
excess cholesterol from the brain in both man and rodents (Bjorkhem et al., 1998; Lund 
et al., 1999).  The enzyme CYP46A1 has been crystallized and the structure has been 
elucidated in detail (Mast et al., 2008). A number of strong inhibitors and modest 
activators of the enzyme has been identified. CYP46A1 was found to have a broad 
substrate specificity including not only steroids but also a number of drugs. This 
enzyme is mainly expressed in the neuronal cells of the brain (Lund et al., 1999) with 
little or no specific transcriptional regulatory mechanism (Ohyama et al., 2006). Unlike 
cholesterol, this monooxygenated molecule, 24S-OH, is able to cross the BBB to the 
circulation, where it is taken up by the liver and converted into bile acids and 
conjugates of un-metabolized or partially metabolised 24S-OH (Bjorkhem et al., 2001).    
 
Neurons are believed to depend on astrocytes for their cholesterol supply, which is 
delivered in an APOE-bound form. Based on in vitro studies, it has been suggested by 
Pfrieger that the flux of cholesterol from astrocytes to neurons is regulated by 24S-OH, 
which is considered as one of the most efficient activators of LXR in vitro (see below). 
Flux of 24S-OH from neurons to astrocytes would be expected to result in transcription 
of the LXR-target genes ABCA1and APOE in glial cells, with a subsequent increase in 
cholesterol efflux (Pfrieger, 2003). This contention is supported by another in vitro 
experiment demonstrating that 24S-OH induces expression of APOE and APOE-
mediated efflux of cholesterol via an LXR pathway (Abildayeva et al., 2006).  
  
1.4.2 27-Hydroxycholesterol 
27-OH is formed by the action of the mitochondrial enzyme sterol 27-hydroxylase 
(CYP27A1), which is widely expressed throughout the body. Under in vitro conditions, 
CYP27A1 is regulated by several molecules, such as cyclosporine A, cholic acid (Segev 
et al., 2001), thyroid hormone, glucocorticoids and growth hormone (Araya et al., 
2003). Moreover, the expression of CYP27A1 is affected by estrogen and androgens 
(Tang et al., 2007). However, the main regulatory factor for CYP27A1 expression in 
vitro as well as in vivo is the substrate availability (Pandak et al., 2002). There is a 
constant flux of 27-OH and metabolites of this oxysterol from extrahepatic tissues to 
the liver, where it is metabolized into bile acids (Lund et al., 1996). At the same time, 
there is significant uptake of 27-OH by the brain, (approximately 5 mg/day), in which it 
is rapidly metabolized into the steroid acid, 7α-hydroxy-3-oxo-4-cholestenoic acid 
(Heverin et al., 2005). This acid is also able to cross the blood-brain barrier, and is 
rapidly eliminated from the brain and metabolized in the liver (Meaney et al., 2007).  
The conversion of cholesterol to 27-OH is considered to be a significant form of 
reverse cholesterol transport, and the absence of this mechanism in CTX patients due to 
absence of the enzyme CYP27A1 contributes to the premature atherosclerosis seen in 
these patients (Bjorkhem et al., 1994).  
 
Moreover, 27-OH is known to be the most prevalent oxysterol in the circulation and its 
levels are closely correlated with those of cholesterol in the circulation (Harik-Khan 
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and Holmes, 1990; Babiker et al., 2005) . Therefore, it has been suggested that a 
number of negative effects of cholesterol in periphery are mediated by its metabolite 
27-OH. It has been reported that 27-OH is an endogenous selective estrogen receptor 
modulator (Umetani et al., 2007; DuSell et al., 2008) which exhibits an antiestrogenic 
action on the vascular endothelium. Furthermore, studies in mouse models of breast 
cancer revealed that 27-OH enhances both tumour growth in an estrogen receptor-
dependent manner, and also the metastatic effect of the cancer cells in an LXR-
dependant manner (Nelson et al., 2013). DuSell et al. demonstrated that increasing 
concentrations of 27-OH have a negative effect on bone homeostasis, since it causes 
decreased bone formation and increased bone resorption (DuSell et al., 2010). 
 
 
1.5 EFFECTS OF THE SIDE-CHAIN OXIDIZED OXYSTEROLS ON 
COGNITION AND MEMORY  
Unlike cholesterol, side-chain oxidized oxysterols are able to cross the BBB. As 
mentioned above, 24S-OH is the major cerebral oxysterol and its plasma levels can be a 
used as a marker for the CNS neuronal mass. Patients with advanced AD have reduced 
levels of plasma 24S-OH (Bretillon et al., 2000; Kolsch et al., 2004). The levels of 
24S-OH are also reduced in chronic multiple sclerosis patients (Leoni et al., 2002; 
Teunissen et al., 2003). Continuous production of 24S-OH is important for memory 
function as indicated by impaired spatial and motor learning, as well as impaired 
hippocampal long-term potentiation (LTP), in mice lacking the gene Cyp46a1 (Kotti et 
al., 2006). Treatment of wild-type hippocampal slices with statins also impairs LTP, 
while treatment with the non-steroid isoprenoid geranylgeraniol, a by-product of the 
mevalonate pathway, normalizes LTP. From these observations, the authors suggested 
that CYP46A1-mediated cholesterol turnover in the brain is necessary to ensure 
adequate production of geranylgeraniol for normal brain function. In line with this, 
studies in old female mice with overexpression of human CYP46A1 showed better 
spatial memory, compared to controls (Maioli et al., 2013). The levels of lanosterol are 
increased in the brains of CYP46A1 overexpressor mice, indicating an increased 
cholesterol synthesis with higher production of geranylgeraniol. Another benefit of 
24S-OH in the brain is its inhibitory effect on the formation of Aβ peptide. Thus 24S-
OH favours the non-amyloidogenic pathway in neuroblastoma cells, while 27-OH 
antagonizes this effect and promotes production of Aβ (Prasanthi et al., 2009). Heverin 
et al., reported that the brain of aged mice expressing the Swedish Alzheimer mutation, 
and the brain of AD patients, contain increased 27-OH and decreased 24-OH  (Heverin 
et al., 2004). In light of this, overexpression of CYP46A1 in the hippocampus of an AD 
model, APP23 mice, markedly reduces Aβ peptides, amyloid deposit, and it also 
improves spatial memory (Hudry et al., 2010). Using a similar approach, 
overexpression of CYP46A1 again demonstrates positive effects in both another AD 
model that expresses Tau pathology, and also in a model of Huntington’s disease 
(Burlot et al., 2015; Boussicault et al., 2016). Furthermore, 24S-OH has been shown to 
be a potent allosteric modulator of N-methyl-D-aspartate receptors (NMDAR) that play 
a critical role in regulating synaptic plasticity (Paul et al., 2013). 
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Mid-life hypercholesterolemia is a risk factor for AD (Kivipelto et al., 2001; Solomon 
et al., 2009), in spite of the fact that the cholesterol pool in the brain is totally isolated 
from the cholesterol pool in the circulation. Thus, it has been suggested that the 
negative effect of hypercholesterolemia on the CNS is mediated by the cholesterol 
oxygenated derivative 27-OH, which is able to cross the BBB. (Bjorkhem et al., 2009). 
In line with this, Mateos et al. reported that dietary cholesterol alters the expression of 
many genes in the brain. Among those genes with altered expression, these scientists 
investigated the gene encoding for the ”memory protein” activity-regulated 
cytoskeleton-associated protein (ARC), which is found to be significantly reduced in 
the cortex and hippocampus after cholesterol feeding (Mateos et al., 2009). This protein 
is normally expressed in the principal neurons in the cortex and hippocampus 
(Vazdarjanova et al., 2006) . ARC expression increases during learning and memory 
training activities, thus it is an important protein in synaptic plasticity and memory 
consolidation (Guzowski et al., 2000; Bramham et al., 2010). In contrast, the 
expression of this ARC protein is reduced in the brain of AD patients (Ginsberg et al., 
2000; Mateos et al., 2009). Treatment of hippocampal primary neuronal cells with 27-
OH inhibits Arc expression (Mateos et al., 2009). In addition, very recently Ismail et al. 
reported that CYP27A1 overexpressor mice, characterized by elevated plasma and 
tissue levels of 27-OH, exhibit decreased glucose metabolism in the brain as well as 
memory deficits. These mice also have decreased expression of Arc in both cortex and 
hippocampus (Ismail M.A.M., 2017). Cumulatively, these results support the 
contention that part of the negative effect of dietary cholesterol on memory and ARC 
expression could be mediated by 27-OH.  
 
In light of the beneficial effects of 24S-OH and the opposite effects of 27-OH, the 
balance between these two steroids is likely to be of importance for neurodegenerative 
processes in the brain. 
 
 
1.6 REGULATORY ROLES OF THE SIDE-CHAIN OXIDIZED 
OXYSTEROLS IN CHOLESTEROL HOMEOSTASIS 
More than 30 years ago, based on in vitro studies, it was hypothesized that oxysterols 
are important physiological regulators of cholesterol homeostasis (Kandutsch et al., 
1978). Since then, this oxysterol hypothesis has been developed as knowledge of 
cholesterol homeostasis has advanced. Based on in vitro experiments, it’s been 
suggested that side-chain oxidized oxysterols reduce cellular cholesterol levels by their 
action at multiple points in the cholesterol homeostasis system, such as reducing 
cholesterol synthesis and uptake, and stimulating cholesterol efflux from the cell. 
Figure 3 demonstrates the different mechanisms by which oxysterols are able to limit 
intracellular cholesterol levels.  
 
1.6.1 Enhanced degradation of HMGCR protein: 
Oxysterols can regulate the enzyme HMGCR at the post-transcriptional level. 
Accumulation of  oxysterols in the endoplasmic reticulum triggers the formation of the 
HMGCR/INSIG complex that leads to ubiquitination and subsequent degradation of the 
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enzyme, resulting in a rapid inhibition of cholesterol synthesis(Sever et al., 2003; 
Goldstein et al., 2006; Jo and Debose-Boyd, 2010). It has been reported that 27-OH 
enhances HMGCR ubiquitination and degradation under in vitro conditions 
(Radhakrishnan et al., 2007). Also Lange et al. showed that endogenous 27-OH is 
important for acute proteolytic inactivation of HMGCR in response to high levels of 
cholesterol (Lange et al., 2008). The half-life of the enzyme HMGCR dramatically 
reduces from longer than 12 hours in sterol-deprived cells, to less than 1 hour in cells 
with high sterol levels (Gil et al., 1985; Goldstein et al., 2006). 
 
1.6.2 Inhibition of the SREBP pathway: 
Cholesterol synthesis is regulated by the controlled movement of SREBP from the ER 
to the Golgi, where it is subjected to a series of cleavages, with subsequent release of 
the active form and its translocation into the nucleus. This movement is inhibited by 
either cholesterol itself or by oxysterols, thus stopping cholesterol synthesis. 
Cholesterol induces conformational changes in SCAP, and as a consequence SCAP 
binds to INSIG. On the other hand, oxysterols inhibit cholesterol synthesis by binding 
to INSIG, followed by binding of INSIG to SCAP. The latter binding prevents 
transportation of the SREBP/SCAP complex to the Golgi and subsequent lipogenic 
gene expression (Radhakrishnan et al., 2007). 
 
1.6.3 Activation of LXR signaling: 
Some of oxysterol’s effects on cholesterol homeostasis are believed to be mediated by 
the nuclear liver X receptor (LXR). The two LKR isoforms LXRα and LXRβ form 
heterodimers with retinoid X receptors (Willy et al., 1995). LXRs have an important 
physiological role in cholesterol and lipid homeostasis, as shown by several studies in 
mice lacking LXR (Peet et al., 1998; Schuster et al., 2002). In rodents, pharmacological 
activation of LXR results in an upregulation of fatty acid synthesis genes e.g. Srebp-1c, 
Fas, the cholesterol efflux genes Abca1, Abcg5, Abcg8, the  bile acid synthesis gene 
Cyp7a1, and also a downregulation of the Cyp7b1 gene that encodes for the main 
enzyme in the alternative bile acid synthesis pathway (Uppal et al., 2007). Activation of 
the LXR can be regarded as a defence mechanism preventing accumulation of excess 
cholesterol in tissues.  
 
Lehmann et al. demonstrated that oxysterols are natural ligands for LXR under in vitro 
conditions (Lehmann et al., 1997).  It has been found that 24(S), 25-epoxycholesterol, 
24S-OH, and 25-OH are the most potent LXR-activating oxysterols. 27-OH is a less 
potent activator of LXR than the aforementioned oxysterols, but this oxysterol is 
present at relatively high levels and has therefore been suggested as a physiological 
activator of LXR. Several in vitro studies have demonstrated the ability of 27-OH to 
activate the LXR-responsive genes, ABCA1, ABCG1and APOE (Kim et al., 2009). Fu 
and colleagues also reported that 27-OH is an activator of ABCA1 and ABCG1 genes in 
cholesterol-loaded fibroblasts (Fu et al., 2001). 
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Figure 3. Regulation of cholesterol homeostasis by oxysterols. The different mechanisms of how side-
chain oxidized oxysterols reduce cholesterol status in the cell by several molecular mechanisms: 1. 
accelerated degradation of HMG-CoA reductase; 2. suppression of SREBP activation; 3. increased 
cholesterol efflux by activating LXR-mediated gene transcription. Reproduced from Brown, A. J. Jessup, W. 
Oxysterols: Sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis. Molecular 
aspects of medicine (Brown, 2009). 
 
 
1.7 IN VIVO STUDIES IN MICE WITH DIFFERENT LEVELS OF SIDE-
CHAIN OXIDIZED OXYSTEROLS 
The important role of oxysterols in bile acid synthesis and in cholesterol transportation 
is well documented. However, the physiological role of oxysterols as regulators of 
cholesterol homeostasis in vivo is still unclear. It should be emphasized that the above 
mechanisms for regulation of cholesterol homeostasis have been demonstrated in vitro, 
and the importance of oxysterols in the regulation of cholesterol homeostasis in vivo in 
the presence of excess cholesterol, is not known with certainty. Oxysterols are present 
in trace amounts only in the circulation and tissues, and are always accompanied by a 
103- to 106- fold excess of cholesterol. In most tissues, this excess of cholesterol in 
relation to oxysterols, might affect the ability of oxysterols to bind to LXR (Bjorkhem, 
2009). In the brain, however, the ratio between a side-chain oxidized oxysterol and 
cholesterol is higher than 1 to 1000. Therefore, there is a higher potential for LXR-
mediated regulation in the brain than in other tissues. 
 
Experiments on mice lacking the gene encoding for the enzyme CYP46A1 revealed a 
reduction in cholesterol biosynthesis in the brain of mutant mice by about 40%, but not 
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in other organs (Lund et al., 2003). This reduction in cholesterol synthesis is mainly 
due to reduced elimination of cholesterol from the brain via its conversion into 24S-
OH. In spite of this, the total cholesterol levels in the brain of the mutant mice are 
normal.  The effect of the knockout of the enzyme CYP46A1 on LXR-target genes in 
the brain was not studied. Behavioral studies in these mice demonstrate severe memory 
defects (Kotti et al., 2006), (see above). 
 
A transgenic mouse model with high levels of 24S-OH has been previously generated 
by our group (Shafaati et al., 2011). These mice overexpress the human enzyme 
CYP46A1 that converts cholesterol to 24S-OH. This overexpression induces 
cholesterol synthesis in these mice, with unchanged cholesterol levels in the brain. It is 
known from in vitro studies that 24S-OH is one of the most efficient LXR activators 
(Janowski et al., 1999). Contrary to expectations, there were no stimulatory effects on 
LXR-target genes in the brain and liver of these transgenic mice (Shafaati et al., 2011). 
These results are consistent with other results obtained by local overexpression of 
CYP46A1 in the cortex and hippocampus of APP23 mice. This group also failed to 
detect any activation of LXR-target genes in the brain of these mice, in spite of elevated 
24S-OH (Hudry et al., 2010). 
 
Knockout of  the enzyme responsible for the formation of 27-OH in mice, CYP27A1, 
results in an approximate 75% decrease in the bile acid pool, reduced intestinal 
cholesterol absorption and increased hepatic cholesterol synthesis. Cholic acid 
supplementation in the diet of these mice reverses all of these symptoms (Repa et al., 
2000b). In a separate study by our group, we found that these mice have a modest 
upregulation of cholesterol synthesis in the brain, as predicted by high lathosterol levels 
(Bavner et al., 2010). This increase in cholesterol synthesis is also observed in the 
brains of mice treated with cholic acid, as well as in non-treated mice. This result is 
consistent with a possible regulatory role of 27-OH in cholesterol synthesis in the brain. 
However, the effects of the knockout of the gene on LXR-target genes were not studied 
in this model. 
 
Overexpression of the human CYP27A1 in mice results in 3-5 fold increase in 27-OH 
in the circulation and extra-cerebral tissues. There is no marked effect on cholesterol 
homeostasis in these mice (Meir et al., 2002). The most striking effect is the reduced 
levels of 24S-OH in the circulation of the overexpressor mice, possibly due to 
metabolism by the overexpressed enzyme (Bjorkhem et al., 2001). Disruption of the 
gene oxysterol 27-hydroxylase (Cyp7b1) in mice also results in markedly high levels of 
27-OH in the circulation and tissues (Li-Hawkins et al., 2000). These mice have normal 
cholesterol levels in the circulation and normal cholesterol synthesis in the liver. The 
possible consequences of the high levels of 27-OH on the expression of LXR-target 
genes were never studied in either of these two models. 
 
A triplet knockout mouse model that lacks 24S-OH, 25-OH and 27-OH in the 
circulation and tissues was generated previously (Chen et al., 2007). Due to the 
consequences of the knockout of Cyp27a1, the mice were treated with cholic acid in the 
diet. Challenging these mice with a high cholesterol diet failed to induce expression of 
some established LXR-target genes in the liver. This result led to the conclusion that 
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some of the effects of cholesterol feeding on LXR-target genes are likely to be 
mediated by side- chain oxidized oxysterols. 
 
The above in vivo studies do not support the contention that side-chain oxidized 
oxysterols are important for cholesterol synthesis and turnover under normal 
conditions, with the possible exception of the situation in the brain. Except for the 
situation with high levels of 24S-OH, the effects of high levels of side-chain oxidized 
oxysterols on LXR-targeted genes have not been studied previously. 
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2 AIMS 
The intention of the present thesis was to use transgenic mouse models with markedly 
changed levels of side-chain oxidized oxysterols to evaluate if such oxysterols are of 
importance in the regulation of cholesterol homeostasis and LXR-target genes in 
different organs. The specific aims were the following: 
 
• Exploring the role of side-chain oxidized oxysterols in cholesterol homeostasis 
in the mouse brain (Paper I). 
 
• Investigating the effect of 27-OH on the expression of cholesterol-synthesis 
genes and LXR-target genes in the liver, under basal conditions and after 
cholesterol feeding (Paper II). 
 
 
• Comparing the effect of 27-OH on cholesterol synthesis in the brain and kidney 
in two different models with elevated 27-OH (Paper III). 
 
• Testing the possibility that the negative effects of cholesterol on cognition is 
mediated by 27-OH (Paper IV). 
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3 MATERIALS AND METHODS 
The following is a brief account of materials and methods used in this thesis. For more 
details, please refer to the respective papers. 
 
3.1 MATERIALS 
3.1.1 Animals 
All mice were 2-5 months old when experiments were conducted. The mice were 
specifically generated for these experiments from our on-going breeding colonies in 
Huddinge University Hospital Animal Facility. The colonies were maintained by 
breeding heterozygous pairs. The animals were housed, in Makrolon type II cages with 
wire tops (Tecniplast, Sweden), under standard environmental conditions with free 
access to food and water. All mice were euthanized by CO2 inhalation at the same time 
of the morning, except for Cyp27a1 knockout mice, which were euthanized by cervical 
dislocation. Blood and tissues were collected and stored at -80°C. 
 
All experiments in these studies were performed in accordance with the guide lines 
from the Swedish national board for Laboratory Animals and the European 
Communities Council Directive of 24 November 1986 (86/609/EEC), and approved by 
the Southern Stockholm Ethical Committee. 
 
3.1.1.1 CYP27A1 transgenic mice (CYP27A1 tg) 
These mice were generated previously using the b-actin promoter (Meir et al., 2002). 
The founders were originally obtained from our collaborator Eran Leitersdorf, and they 
were on C57BL/6 background. In this experiment C57BL/6 mice were used as a 
control group, and were purchased from Charles River Laboratories, Germany. 
 
3.1.1.2 Cyp27a1 knockout mice (Cyp27a1-/-) 
This strain was also generated previously on a C57BL/6 background (Rosen et al., 
1998). Homozygous knockout mice and their corresponding wild-type controls were 
generated from the breeding of heterozygous mice. These mice have a deficient 
production of bile acids that leads to a malabsorption of cholesterol and other lipids. As 
a consequence of this, they have a compensatory increase in cholesterol synthesis and 
an increased activity of CYP7A1, corresponding to the rate-limiting step in the 
formation of bile acids. Treatment of the mice with cholic acid normalizes cholesterol 
absorption and cholesterol synthesis. Because of this, we treated the Cyp27a1-/- mice 
with either 0.05% cholic acid or 0.025% cholic acid for three months before euthanasia 
at the age of four months (Repa et al., 2000b). In addition to cholic acid, the diet was 
supplemented by either 1% cholesterol for the last seven days, or with 0,05% 
cholesterol for the last three months before euthanasia. The different diets were 
obtained from Lantmännen and Harlan Teklad 2918. 
 
3.1.1.3 Cyp7b1 knockout mice (Cyp7b1-/-) 
The Cyp7b1-/- mice used in this project were generated in another laboratory, as has 
been described previously (Rose et al., 2001). They were on C57BL/6 background. As 
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for Cyp27a1-/- mice, homozygous knockout mice and their corresponding wild-type 
controls were generated from the breeding of heterozygous mice.   
 
 
 
3.2 METHODS 
3.2.1 Lipid extraction and analysis 
Livers and brains were extracted according to Folch method. Folch solution 
(chloroform/methanol 2:1, v:v), 3 and 10 ml, was added to about 100 mg liver tissue, 
and to half of a brain or a hippocampus or cortex from half of a brain, respectively. 
After 24 hours at room temperature, the extracts were transferred to new vials and 
evaporated under argon. After evaporation, the extracts were re-dissolved in 1 ml 
(liver) or 10 ml (brain) Folch and stored at -20°C until required. Sterols and oxysterols 
were measured in the Folch extract by gas chromatography–mass spectrometry after 
alkaline hydrolysis using deuterium-labelled internal standards as previously described 
(Dzeletovic et al., 1995; Acimovic et al., 2009). In some experiments, the hydrolysis 
step was excluded in order to measure the fraction of unesterified oxysterol. 
 
3.2.2 RNA preparation and real-time PCR 
Total RNA was extracted from liver and brain tissues either by TRIzol reagent, or with 
RNAeasy lipid tissue Mini kits (Qiagen, CA, USA) following the manufacturer's 
protocol. Total RNA was reverse-transcribed using High-capacity cDNA Reverse 
Transcription kit (Applied Biosystems, Foster City, CA). The relative expression levels 
of target genes were determined by real-time RT-PCR amplification assays (Applied 
Biosystems). All values were normalized either to HPRT or GAPDH mRNA 
concentrations. The relative quantification of gene expression was carried out using the 
comparative cycle threshold method, 2−∆∆Ct (Livak and Schmittgen, 2001). Each 
sample was measured in triplicate. 
 
3.2.3 Western blotting 
All Western blots were made with whole homogenates of livers. Antibodies toward 
ABCA1 (ab1811180), lipoprotein lipase (LPLA4) (ab21356) and Actin (ab8227) were 
obtained from Abcam. Antibodies toward ABCG8 protein were from Santa Cruz 
Biotechnology (H-300: sc-30111) and Novus Biologicals Cambridge UK (NB400-
117SS), and antibodies toward SREBP1C protein were from BD Biosciences (Cat# 
557036). Antibodies toward ABCG5 protein were a generous gift from Dr. Ligin You, 
Wake Forest University School of Medicine, Winston-Salem, NC. The incubation with 
primary antibodies was followed by incubation with anti-rabbit or anti-mouse 
immunoglobulin G (IgG) at 1:10000 dilutions and Li-COR IR Dye secondary antibody 
at 1:15 000 dilutions. The relative density of the immune-reactive bands was calculated 
from the optical density (OD) multiplied by the area of the selected band using Odyssey 
Fc Imager software. 
 
3.2.4 Lipoprotein lipase activity 
Frozen tissue samples were homogenized in 9 volumes of a buffer containing 0.025 M 
ammonia, 1% Triton X-100, 0.1% SDS, 5 IU heparin/ml and protease inhibitor cocktail 
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tablets, pH 8.2 (Complete Mini, Roche Diagnostics, Germany, 1 tablet/50 ml). After 
homogenization (Bullet Blender Blue CE, Next Advance co, USA), samples were taken 
for analyses of LPL activity using a commercial emulsion of soy bean triacylglycerols 
in egg yolk phospholipid (Intralipid 20% from Fresenius Kabi, Uppsala, Sweden), into 
which 3H-oleic acid labeled trioleolylglycerol was incorporated by intermittent 
sonication for 5 min (in an ice bath). Triplicates were analyzed from each sample in a 
total volume of 200 µl. The incubations were carried out for 2 h at 25-°C, and the 
reactions were stopped by addition of organic solvents for extraction of the fatty acids 
by the method of Dole, as described (G.Bengtsson-Olivecrona, 1992). The enzyme 
activity is expressed as mU per g tissue wet weight where 1 mU corresponds to the 
release of 1 nmol fatty acids per min.  
 
3.2.5 Morris water maze test 
The Morris water–maze (MWM) is a circular pool constructed of grey PVC, 160 cm in 
diameter and 45 cm in height (Morris, 1984). The MWM protocol was adapted from 
Gao et al. (Gao et al., 2011). Briefly, the pool is filled with water and rendered opaque, 
using non-toxic tempera paint to form a contrast with the mouse's body for the 
automated tracking software to detect the mouse. The water is kept at a temperature of 
21 ± 1 °C. A transparent plastic square platform (9 cm × 9 cm) is placed approximately 
1 cm below the water surface and 10 cm from the edge of the pool. Distal visual cues 
consist of several wall posters of approximately 0.50 × 0.75 m in size that surround the 
pool. The whole experiment consists of three phases. (1) Water adaptation trial: to test 
for stamina and to habituate the mice to the water, (2) Acquisition learning test and 
probe test, (3) Visual cue tests.  Performance in the MWM test was monitored with 
EthoVision video-tracking system (Noldus Information Technology, Wageningen, The 
Netherlands). 
 
3.2.6 Statistics 
Real-time RT-PCR data and sterol measurements were analyzed by unpaired Student t-
test, except in paper IV, where a Mann–Whitney test was used. All the data are shown 
as means ± SEM. The level of statistical significance was set at p < 0.05 for all 
parameters. 
 
Morris water–maze tests were analyzed with repeated measurements analysis of 
variance (ANOVA), followed by the Bonferroni post hoc test, using SPSS software. All 
data are presented as group mean values ±SEM. 
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4 RESULTS AND DISCUSSION 
 
4.1 ON THE REGULATORY ROLE OF SIDE-CHAIN HYDROXYLATED 
OXYSTEROLS IN THE BRAIN. LESSONS FROM CYP27A1 
TRANSGENIC AND CYP27A1-/- MICE (PAPER I) 
4.1.1 Effects of overexpression and knockout of the gene CYP27A1 on 
cholesterol synthesis 
Plasma and brain levels of 27-OH were about 6- and 11- fold higher in transgenic mice 
than in controls, respectively. 27-OH is a suppressor of cholesterol synthesis under in 
vitro conditions. Therefore, we would expect a suppression of cholesterol synthesis in 
the brain of transgenic mice. We observed, however, an increase in cholesterol 
synthesis in the brain of the CYP27A1tg mice, as shown by the elevated mRNA levels 
of Hmgcr, Hmgcs, and Srebp2 in the brains of these animals (Figure 4c). In accordance 
with this, most of the cholesterol precursors in the brain of these mice were also 
increased (Figure 4a).  
 
There was an approximate 25% reduction in the major cerebral oxysterol 24S-OH. It 
has been demonstrated previously that 24S-OH is metabolized by CYP27A1 
(Bjorkhem et al., 2001), which could be the cause of the low levels of 24S-OH. It is 
most likely that this reduction in the levels of 24S-OH, which is known to be a 
suppressor of cholesterol synthesis in neuronal cells (Wang et al., 2008), is the reason 
for the increased cholesterol synthesis. In spite of the high levels of 27-OH in the brain 
of transgenic mice compared to the controls, the levels are still much lower than the 
concentration of 24S-OH in the brain.  
 
There is another possibility that the increased cholesterol synthesis in the brains of the 
transgenic mice is a compensatory mechanism due to the increased consumption of the 
brain cholesterol by the overexpressed enzyme. It seems less likely that such a 
metabolic pathway could be of major importance, since the normal expression of 
CYP27A1 in the brain is low, and it is believed that most cerebral 27-OH originates 
from the circulation (Heverin et al., 2005). There was no tendency to reduced levels of 
cholesterol in CYP27A1tg mice (Figure 4a).  
 
Knockout of the Cyp27a1 gene also resulted in increased cholesterol synthesis in the 
cortex of brains of Cyp27a1-/- mice, as judged by the detection of increased cholesterol 
precursors (Figure 4b). This result is consistent with previous studies of the brain of this 
model (Bavner et al., 2010) and has also been confirmed by other groups (Pikuleva I, 
unpublished experiments). The most likely explanation for the increased cholesterol 
synthesis in these mice is the lack of normal flux of 27-OH into the brain that has a 
slight inhibitory effect on cholesterol synthesis. It should be pointed out that these mice 
were treated with cholic acid to compensate for their reduced bile acid synthesis. In 
theory, bile acid alone could have effects on cholesterol homeostasis in the brain. In the 
previous work, however, the same results were obtained with both un-treated mice and 
with mice treated with cholic acid. 
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Figure 4. The effects of 27-OH on cholesterol synthesis and LXR-target genes in the adult brain of 
male mice from different mouse models. (a), the effect of overexpression of human CYP27A1 on the 
levels of cholesterol and cholesterol precursors in the brain of CYP27A1 transgenic mice; (b) levels of 
cholesterol and cholesterol precursors in the brain of Cyp27a1 knockout mice; (c) and (d) mRNA levels 
of SREBP-regulated and LXR-regulated genes in the brain of CYP27A1 transgenic mice and Cyp27a1 
knockout mice, respectively. n = 7-10 in each experiment. Data are presented as mean ± SEM. * P < 0, 
05. 
 
 
4.1.2 Theoretical model for regulation of cholesterol homeostasis in the 
brain 
The main players in the regulation of cholesterol homeostasis in the brain seem to be 
HMGCR and CYP46A1. Similar to the situation in the liver, Hmgcr is subject to tight 
regulation in the brain in order to keep the cerebral cholesterol pool at a constant level. 
On the other hand, Cyp46a1 is subject to very little regulation at the transcriptional 
level (Ohyama et al., 2006). Combining the present results with previous results (Lund 
et al., 2003; Wang et al., 2008; Bavner et al., 2010; Shafaati et al., 2011), we arrived at 
the regulatory model shown in Figure 5. This model is consistent with all present 
results, in vivo and in vitro, but further studies may be needed for confirmation.  
 
Given the fact that 24S-OH is a substrate for the enzyme CYP27A1, we believe that the 
increased activity of this enzyme is the explanation for the reduced levels of 24S-OH 
seen in the brain and circulation of our mouse model. It should be emphasized that 
reduced levels of 24S-OH in the brain may be the consequence not only of increased 
metabolism in the brain but also outside the brain (Figure 5). Reduced levels of 24S-
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OH in the circulation lead to an increased concentration gradient of the oxysterol 
between the brain and the circulation, which may lead to increased flux from the brain. 
 
After publication of the above results, additional support has been obtained for the 
contention that the level of 24S-OH in the brain is of importance for cholesterol 
synthesis in this organ. In a recent study, our group characterized cholesterol 
homeostasis in the brain of a mouse model with pericyte-deficiency resulting in a 
leaking blood-brain barrier (Saeed et al., 2014). The defective BBB resulted in a flux of 
cholesterol from the circulation into the brain and an increased flux of 24S-OH from 
the brain into the circulation. The latter flux leads to a reduction in the level of 24S-OH 
in the brain that was reminiscent of the reduced levels of 24S-OH in the brain of our 
CYP27A1tg mice. Also, in this case the reduced levels of 24S-OH were associated with 
increased cholesterol synthesis in the brain. If the increased levels of 27-OH in the 
brain of CYP27A1tg mice had been the reason for the increased cholesterol synthesis, 
the same effect would have been expected in the brain of Cyp7b1-/- mice. However, 
neither cholesterol synthesis genes nor cholesterol precursors were affected by the high 
levels of 27-OH in this mouse model, and the levels of 24S-OH were similar to those of 
controls (Paper IV, unpublished results). 
 
 
 
 
         
 
 
 
Figure 5. Theoretical model for the regulation of cholesterol homeostasis in the brain. 
 
 
It should be emphasized that the above model represents a self-regulated system. A 
primary increase in cholesterol synthesis in the brain leads to some increase in the level 
 20 
of 24S-OH which counteracts the increased cholesterol synthesis. A primary decrease 
in production of 24S-OH or an increased leakage of this oxysterol will lead to increased 
cholesterol synthesis that will counteract the decreased level of 24S-OH. This is a 
finely tuned system designed to keep the cholesterol levels in the brain as constant as 
possible. Upregulation or downregulation of the genes involved in the mechanism did 
not lead to changes in the cholesterol levels measured in the whole brain. It has been 
reported, however, that overexpression of CYP46 in mouse brain leads to slightly 
reduced levels of cholesterol in isolated neuronal membranes (Moutinho et al., 2015). 
 
4.1.3  Effects of overexpression and knockout of the gene Cyp27a1 on 
LXR-targeted genes 
In contrast to our expectations, the overexpression of CYP27A1 led to moderate 
changes only in the expression of LXR-targeted genes. Some of the LXR-target genes 
(Abcg1, Abca1, and Srebpc1) were slightly decreased by the overexpression rather than 
increased (Figure 4c). On the other hand, there were no changes in LXR-target genes in 
the brain of the Cyp27a1-/- mice (Figure 4d). 
 
It has been reported that sulphation of 25-OH is an antagonist mechanism for the 
oxysterol-dependent activation of LXR (Xu et al., 2010). Therefore, we considered the 
possibility that the opposite effect on LXR target genes that we observed could be due 
to a sulphated form of 27-OH. In a previous study from our laboratory, we found that 
the fraction of the total level of the sulphated 27OH in the CYP27A1tg mice is similar 
to that in wild-type mice (Acimovic et al., 2013). Thus, it seems less likely that 27-OH 
sulphate is of importance for the effects observed. 
 
An alternative explanation is that reduction in the pool of 24S-OH is the cause of the 
above opposite effect, since 24S-OH is an efficient activator of LXR in vitro. In a 
previous study on mice with high levels of 24S-OH in the brain, there was normal 
expression of LXR-target genes in the brain (Shafaati et al., 2011). The same result was 
obtained from another recent study on the pericyte-deficient mouse model that has 
reduced levels of 24S-OH in the brain (Saeed et al., 2014). The results from these two 
studies do not support the hypothesis that reduced levels of 24S-OH is the cause of the 
downregulation of LXR-target genes observed in the brain of the transgenic mice. It 
should be emphasized that here, we studied the effect in the whole brain and this might 
mask any specific effects that could have occurred in specific locations of the brain. 
 
In conclusion, our data in this study does not support the contention that 27-OH and 
24S-OH are important activators of LXR in the brain, at least under normal conditions. 
It seems likely, however, that 24S- and 27-OH have a suppressive effect on cholesterol 
synthesis in the brain.  
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4.2 ON THE REGULATORY IMPORTANCE OF 27-
HYDROXYCHOLESTEROL IN MOUSE LIVER (PAPER II) 
4.2.1 Effects of 27-OH on cholesterol synthesis and LXR-target genes 
in the liver 
It has been shown that 27-OH is a strong inhibitor of cholesterol synthesis under in 
vitro conditions (Axelson and Larsson, 1995; Schroepfer, 2000); however, the potential 
of 27-OH to affect cholesterol synthesis in vivo, under normal condition, is still 
uncertain. In this study, we were interested in investigate the effect of this oxysterol on 
cholesterol homeostasis  and LXR-target genes in the liver of our two mouse models, 
Cyp7b1-/- and CYP27A1tg mice, which exhibit high levels of 27-OH in the circulation 
and tissues; we additionally included a model with undetectable levels of 27-OH in the 
circulation, Cyp27a1-/- mice. The advantage of using two different models with high 
levels of 27-OH is that, any effect due to 27-OH itself should be seen in both models. 
 
Since 25-OH is also metabolized by CYP7B1, it accumulates in the liver of Cyp7b1-/- 
mice to an extent similar to 27-OH in the liver of CYP27A1tg mice. Like the situation 
with 27-OH, 25-OH is also an efficient suppressor of cholesterol synthesis. Because of 
this, we expected reduced cholesterol synthesis in the livers of both mouse models with 
high levels of 27-OH, with the highest inhibition in the liver of the Cyp7b1-/- mice. 
Opposite to our expectations, there was no effect on cholesterol synthesis either in the 
liver of Cyp7b1-/- mice, or in CYP27A1tg mice. There were normal mRNA levels of 
cholesterol-synthesis genes (Hmgcr, Hmgcs, and Srebp2) as well as normal levels of 
most cholesterol precursors in the liver (Figure 6).  If 27-OH is an important inhibitor 
of cholesterol synthesis in vivo, then an increase in cholesterol synthesis could be 
expected in the liver of Cyp27a1-/- mice, which is not the case here. Our results are in 
agreement with previous results (Li-Hawkins et al., 2000), which failed to detect 
effects on cholesterol synthesis in the liver of Cyp7b1-/- mice. The results are also 
consistent with previous work in our laboratory, which could not demonstrate critical 
roles for 24S-, 25 or 27-hydroxycholesterol in cholesterol-induced downregulation of 
Hmgcr in mouse liver (Lund et al., 1992). However, the situation might be different 
under some other pathological conditions. Kannenberg et al. reported a marked 
elevation of 24-, 25-, and 27-OH in fibroblasts from Tanger’s disease patients 
combined with decreased cholesterol synthesis (Kannenberg et al., 2013). 
 
In fact, 27-OH is a less potent activator of the LXR mechanism than other oxysterols. 
At the same time, it is present at  higher concentrations than any other oxysterol in the 
circulation and all tissues, except for the brain. Therefore, we expected a possible 
upregulation of  LXR-targeted genes in the liver of Cyp7b1-/- and CYP27A1tg mice, due 
to the high levels of 27-OH in their circulation and liver. On the contrary, there were no 
effects in the liver of Cyp7b1-/- mice (Figure 6c), while there was a slight upregulation 
of the genes Abca1 and Cyp7b1 in CYP27A1tg mice (Figure 6d). If the effect on Abca1 
is due to the high levels of 27-OH, it should be seen in both models. Activation of LXR 
would result in inhibition of the gene Cyp7b1 rather than activation (Uppal et al., 
2007). A previous study by our group (Shafaati et al., 2011) on the liver of CYP46A1tg 
mice with high levels of 24S-OH in their circulation, also failed to demonstrate any 
activation of LXR-target genes in spite of the fact that 24S-OH is a potent activator of 
 22 
LXR (Janowski et al., 1996). There were no differences in the expression of the LXR-
target genes between the Cyp27a1-/- mice and their controls. 
 
Most of the oxysterols in the liver and circulation (90%) are present in the esterified 
form (Dzeletovic et al., 1995; Li-Hawkins et al., 2000), and we confirmed this 
observation here. The presence of 27-OH mainly in the esterified form, which is 
believed to be the inactive form of the oxysterols, could be the explanation for the 
failure of 27-OH to exert any effect on cholesterol synthesis and LXR in the livers of 
Cyp7b1-/- and CYP27A1tg mice.  
 
The results from different models suggest that 27-OH is unlikely to be an important 
regulator of cholesterol synthesis and LXR in the liver under basal conditions. 
However, the situation might be different under some specific pathological conditions. 
 
Figure 6.  The effect of 27-OH on the cholesterol homeostasis in the liver. Cholesterol and cholesterol 
precursors in the liver of Cyp7b1 knockout mice (a), CYP27A1 transgenic mice (b) and mRNA levels of 
SREBP-regulated and LXR-regulated genes in the liver of Cyp7b1 knockout mice (c), CYP27A1 
transgenic mice (d). n = 7-10 in each experiment. Data are presented as mean ± SEM. * P < 0,05. 
 
4.2.2 Effects of cholesterol feeding on LXR-targeted genes in the liver 
It is known that feeding mice with a high dose of dietary cholesterol, which likely 
elevates oxysterol levels, results in an upregulation of a number of LXR target genes in 
the liver (Peet et al., 1998; Chen et al., 2007). Chen et al. tested the hypothesis that 
oxysterols are important mediators of the cholesterol-induced activation of the LXR 
system in vivo, using a triple knockout mouse model that lacks the hydroxylases 
required for the formation of 25-, 24-, and 27-OH (Chen et al., 2007). Since 27-OH is 
the major oxysterol in the circulation and extra-cerebral tissue, it would be of interest to 
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evaluate its role in dietary cholesterol-induced activation of LXR. Thus, we repeated 
the same experiment using a mouse model lacking only the enzyme CYP27A1, 
maintained on a diet supplemented by cholic acid to compensate for the low cholic acid 
levels in this model (Repa et al., 2000b). 
 
As expected the expression of the LXR target genes Abcg5, Abcg8, Srebp1c, Cyp7a1, 
and Lpl, were significantly increased after 1% cholesterol feeding in wild-type (Figure 
7). In the case of Abcg8, Srebp1c, and Lpl, this increase did not occur in cholic acid-
supplemented Cyp27a1-/- mice, indicating that 27OH is a mediator of the response to 
high cholesterol on these three genes. Attempts were made to see if the above changes 
in mRNA levels of these genes were reflected at the protein levels, but we failed to 
demonstrate any significant stimulatory effect of cholesterol feeding on the protein 
levels of ABCG8, or on the activity of LPL enzyme, both in the wild-type mice and in 
Cyp27a1-/- mice. 
 
In the experiment of Chen et al., the stimulatory effect of cholesterol on the expression 
of the Srebp1c gene was not impaired in mutated mice, as was also observed in our 
experiment (Chen et al., 2007). Furthermore, they observed that the cholesterol-induced 
effect on Abcg5 was impaired in their mutated mice. In our study, we observed effects 
similar to those of Chen et al. at the protein level, with a significant increase in Abcg5 
protein due to cholesterol treatment in wild-type mice but not in Cyp27a1-/- mice. We 
saw a reduction in the expression of Fas as a result of dietary cholesterol treatment in 
wild-type mice, while no difference was observed in the expression of Fas in cholic 
acid-substituted Cyp27a1-/- mice.  It is known that Fas is an LXR-target gene and is 
stimulated both by synthetic LXR agonists and by dietary cholesterol (Repa et al., 
2000a). Conversely, other studies have shown that treatment with dietary cholesterol 
reduces Fas expression in rodents (Kim et al., 2002; Marseille-Tremblay et al., 2007; 
Wang et al., 2010). The normal expression of Fas in the Cyp27a1-/- group is consistent 
with the possibility that 27-OH is involved in a suppressive effect of cholesterol 
treatment on the expression of Fas. 
 
The results from our work on Cyp27a1-/- mice, in combination with the previous work 
on the triple knockout mice, suggest that 27-OH is a mediator of cholesterol-induced 
effects on LXR target genes when the mice are challenged with a high load of dietary 
cholesterol. With respect to the physiological importance of our findings, it should be 
emphasized that the cholesterol-enriched diet needed to obtain effects on the LXR 
target genes is highly un-physiological.  
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Figure 7. The effect of cholesterol feeding on LXR-target genes in the livers of cyp27a1-/-, and wild-
type control mice. Data are presented as mean ± SEM. * P < 0,05. 
 
 
4.3 TWO DIFFERENT MOUSE MODELS WITH HIGH LEVELS OF 27-
HYDROXYCHOLESTEROL IN KIDNEY AND BRAIN: A COMPARISON 
(PAPER III) 
In this study our aim was to compare the regulatory role of 27-OH on cholesterol 
homeostasis in the brain and the kidney of two mouse models, CYP27 A1 
overexpressor (CYP27A1tg) and Cyp7b1-/- mice, which both exhibit markedly elevated 
27-OH in their circulation and tissues.  
 
Cyp7b1-/- mice have high levels of 27-OH and 25-OH, while CYP27A1tg mice also 
have high 27-OH but reduced levels of 24S-OH in the brain. We suggested that the 
increase in cholesterol synthesis detected in the brain of CYP27A1tg mice is most 
likely due to the release of the inhibition on cholesterol synthesis as a consequence of 
the reduction in levels of 24S-OH. In order to confirm this, we utilized the Cyp7b1-/- 
mouse model. The levels of the side-chain oxysterol 27-OH were similar in the brains 
of the two strains; however 25-OH, which is also an inhibitor of cholesterol synthesis 
(Radhakrishnan et al., 2007), is about 14-fold higher in the brains of Cyp7b1-/- mice 
compared to those of CYP27A1tg mice. Thus, we expected that the higher amount of 
the total oxysterols in the brain of the knockout model might be able to induce an 
inhibitory effect on cholesterol synthesis. Knockout of the gene Cyp7b1, however, had 
no effect on the levels of cholesterol precursors, or on the expression of SREBP-target 
genes. As described above, the levels of 24S-OH were unchanged in the brains of the 
Cyp7b1-/- mice. In combination with the results of Paper I, these results emphasize the 
regulatory role of 24S-OH levels on cholesterol synthesis in the brain. It should be 
emphasized that these levels are markedly higher than those of 27-OH and 25-OH in 
the brain. 
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However, the situation is different in the kidney of Cyp7b1-/- mice, in which an 
inhibition of cholesterol synthesis was demonstrated previously (Li-Hawkins et al., 
2000). Here, we confirmed this finding as proved by downregulation of the mRNA 
levels of the Hmgcr, the rate limiting enzyme in the cholesterol synthesis pathway 
(Figure 7c). Also, we confirmed the previous finding that side-chain oxidized 
oxysterols mainly exist in the form of free oxysterols in the kidney of the Cyp7b1-/- 
mice. Although the free fraction of oxysterol is also elevated in the kidney of 
CYP27A1tg mice (Figure 8a & 8b), there was no inhibition on cholesterol synthesis, as 
indicated by normal mRNA expression for the gene Hmgcr (Figure 8d). For this 
reason, it seems unlikely that the inhibition of cholesterol synthesis observed in the 
kidney of the Cyp7b1-/- male mice is due to increased levels of free oxysterols. We 
cannot completely exclude the possibility, however, that the combined suppressive 
power of the increased levels of both 25-OH and 27-OH in the kidneys of the Cyp7b1-/- 
is larger than the suppressive power of the increased levels of 27-OH in the 
CYP27A1tg mice. 
 
Figure 8. Oxysterols levels and SREBP-target gene expression in the Kidney of Cyp7b1-/- and 
hCYP27a1 overexpressor mice (Tg) and their wild-type controls. A, free and total 24-, 27-, and 25-
hydroxysterols in Cyp7b1-/-mice. B, free and total 24-, 27-, and 25-hydroxysterols in hCYP27 
overexpressor (hCYP27a1 Tg) mice. C, relative mRNA expression of the SREBP-target genes in Cyp7b1-
/- 
mice. D, relative mRNA expression of the SREBP-target genes in hCYP27 overexpressor (hCYP27 Tg). 
n = 3- 4 males in each group. Data are presented as mean ± SEM. * P < 0.05. 
 
In addition to the metabolism of the oxygenated derivatives of cholesterol, the enzyme 
CYP7B1 also metabolizes some intermediates in the steroid hormone synthesis 
pathway such as dehydroepiandrosterone (DHEA), pregnenolone and the estrogen 
agonist 5α-androstane-3β,17β-diol (3β-Adiol) (Weihua et al., 2002). Combining this 
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with the fact that CYP7B1 has a sexual dimorphic pattern of expression (Schwarz et 
al., 1997; Rose et al., 2001) and is highly expressed in the male kidney, this suggests 
an important role for this enzyme in the male kidney in a manner which is not clear 
yet. Therefore, knockout of the gene Cyp7b1 may result in several consequences such 
as accumulation of the sex hormone precursor DHEA in the circulation and tissues that 
might lead to an unbalanced sex hormone synthesis and a disturbance in the estrogen 
signaling. It has been reported that DHEA inhibits HMGCR expression and activity in 
a pre-neoplastic liver nodule (Pascale et al., 1995)). Also, it has been reported that 
disturbances in estrogen signaling may affect cholesterol homeostasis (Choi and Song, 
2009)). Further studies are needed to clarify the link between loss of Cyp7b1-/- and 
reduced synthesis of cholesterol in the kidney. 
 
To summarize, our failure to detect an effect on cholesterol synthesis in the brain of the 
Cyp7b1-/- in spite of elevated oxysterols, indicates that 27-OH is not an important 
regulator of cholesterol homeostasis in the brain of the Cyp7b1-/- mice. In combination 
with the results presented in Paper I, this finding gives further support for a regulatory 
role of 24S-OH in the brain. On the other hand, the reduced cholesterol synthesis in the 
kidney of the Cyp7b1-/- mice is not likely to be due to the high levels of 27-OH. 
 
 
4.4 27-HYDROXYCHOLESTEROL MEDIATES NEGATIVE EFFECTS OF 
DIETARY CHOLESTEROL ON COGNITION IN MICE (PAPER IV) 
 
There is a growing body of data in the literature connecting mid-life 
hypercholesterolemia to the development of AD later in life (Kivipelto et al., 2001; 
Whitmer et al., 2005; Solomon et al., 2009; Altman and Rutledge, 2010). It has been 
shown that dietary cholesterol may result in reduced memory function in mice 
(Thirumangalakudi et al., 2008). The facts that the serum cholesterol pool is completely 
isolated from the brain cholesterol pool, and the inability of the serum cholesterol to 
cross the BBB (Bjorkhem and Meaney, 2004), led us to hypothesis that the cholesterol-
induced effect on cognition is mediated by 27-OH, which can pass the BBB. It is 
known that there is a close relation between levels of cholesterol and 27-OH in the 
circulation (Babiker et al., 2005). Thus, higher levels of cholesterol in the circulation 
can be expected to lead to a higher flux of 27-OH into the brain. 
 
To test our hypothesis that the negative effects of dietary cholesterol on cognition are 
mediated by 27-OH, we used our Cyp27a1-/- mouse model and their wild-type controls. 
Since Cyp27a1-/- mice have a reduced production of bile acids and reduced capacity to 
absorb cholesterol and other lipids (Repa et al., 2000b), their diet was supplemented 
with 0.05% cholic acid. 
 
Cholesterol feeding to Cyp27a1-/- mice resulted in a slower swimming speed compared 
to the other three groups. Mutations in the CYP27A1 gene in humans, in contrast with 
mice, results in a disease called Cerebrotendonous Xanthomatosis (CTX). This disease 
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is characterized by cholestanol-containing xanthomas in brain and tendon. It has been 
reported that peripheral neuropathy, in particular of the subtype axonal sensory-motor 
neuropathy, is common in CTX patients (Chen et al., 2011). We speculated that the 
combined effect of the lack of the enzyme Cyp27a1and high cholesterol feeding of 
knockout mice might lead to some peripheral neuropathy with disturbances in motor 
function. However, this has not been studied before in the Cyp27a1-/- mice and further 
work is needed to test this hypothesis. 
 
During the acquisition part of the Morris water maze test, all groups of mice were able 
to learn the task as indicated by the decrease in the distance moved over the days 
(Figure 9a). A significant difference was detected between wild-type mice on 
cholesterol (wt-chol) and their wild-type controls on chow (wt-chow), since the wt-chol 
mice needed to move a longer distance to reach the hidden platform. This high 
cholesterol-induced memory impairment in wild-type mice is in line with the previous 
studies reporting diminished memory performance in mice fed a high cholesterol diet 
(Plath et al., 2006; Thirumangalakudi et al., 2008; Ghodke et al., 2012). On the other 
hand, Cyp27a1-/- mice on either cholic acid (KO-CA) or cholesterol plus cholic acid 
(KO-chol + CA) showed similar distances over the days, indicating that the spatial 
learning in Cyp27a1-/- mice was not affected by the diet (Figure 8a.  
 
  
 
 
Figure 9. (a) Acquisition phase in MWM test of wild-type and Cyp27KO mice fed on different diets: 
data are shown as distance moved (cm) to the hidden platform over 6 training sessions. Results are 
expressed as mean ± SEM, n = 8–12 animals per group. (b) ARC expression levels in the hippocampus 
of Cyp27KO and wild-type mice fed on different diets: data are presented as mean ± SEM (*p < 0.05). 
 
Next, we investigated the effect of high cholesterol feeding on the expression of the 
“memory protein” activity-regulated cytoskeleton-associated protein, (ARC). This 
protein is mainly expressed in the hippocampus and is important for the maintenance of 
long-term potentiation (LTP) and for memory consolidation (Lyford et al., 1995; 
Guzowski et al., 2000; Plath et al., 2006). Mateos et al. reported that high cholesterol 
feeding decreases ARC protein levels in the mouse brain, and also that addition of 27-
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OH decreases the level of ARC in the rat primary hippocampal neurons (Mateos et al., 
2009). In accordance with these findings, we detected a downregulation of Arc mRNA 
levels in the hippocampus of wild-type mice treated with cholesterol, while its 
expression in the hippocampus of the Cyp27a1-/- mice was unchanged after cholesterol 
feeding (Figure 9b). These results are consistent with the possibility that at least part of 
the negative effects of dietary cholesterol are mediated by ARC through 27-OH. Other 
mechanisms cannot, however, be excluded. Hypercholesterolemia can induce several 
inflammatory markers that affect cerebral microcirculation that could lead to cognitive 
dysfunction (Thirumangalakudi et al., 2008). Interestingly it was recently reported that  
feeding rabbits a high cholesterol diet  is associated with both higher levels of 27-OH in 
the brain and also hippocampal degeneration in association with altered expression of  
estrogen receptors (Brooks et al., 2017). 
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5 CONCLUSIONS  
 
In the present thesis, we investigated the regulatory role of side-chain oxidized 
oxysterols on cholesterol homeostasis and on cognition using different mouse models. 
 
Paper I – In the brain, both 24S-OH and 27-OH have a suppressive effect on 
cholesterol synthesis in vivo, and 27-OH is not a general activator of LXR.  
 
Paper II – It seems that 27-OH is not an important regulator of cholesterol 
homeostasis, or an activator of LXR-target genes under basal conditions in the liver. 
However, when the system is challenged with a high load of dietary cholesterol, the 
cholesterol-induced effects on some of the LXR target genes in the liver may be 
mediated by 27-OH. 
 
Paper II – Here, after comparing the effects of high 27-OH on cholesterol synthesis in 
the brain and kidney of two different models, we confirmed the regulatory importance 
of 24-OH on cholesterol synthesis in the brain. Factors other than high levels of 27-OH 
are likely to be important for the reduced cholesterol synthes reported in the kidney of 
Cyp7b1-/- mice. 
 
Paper IV– We show that the negative effects of dietary cholesterol on cognition are 
mediated by 27-hydroxylation 
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